{
  "description": null,
  "compose": {
    "include": [ {
      "system": "http://www.cms.gov/Medicare/Coding/ICD10",
      "concept": [ {
        "code": "XW033H5",
        "display": "Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"
      }, {
        "code": "XW043H5",
        "display": "Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5"
      } ]
    } ]
  },
  "_filename": "ValueSet-2.16.840.1.113883.3.3616.200.110.102.4019.json",
  "package_name": "us.nlm.vsac",
  "date": "2023-06-21T18:16:37-04:00",
  "meta": {
    "profile": [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ],
    "versionId": "5",
    "lastUpdated": "2020-12-17T01:00:39.000-05:00"
  },
  "publisher": "Clinical Architecture",
  "jurisdiction": [ {
    "extension": [ {
      "url": "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
      "valueString": "UNKNOWN"
    } ]
  } ],
  "purpose": "(Clinical Focus: This set of values contains terms related to administration of tocilizumab.),(Data Element Scope: ),(Inclusion Criteria: Includes introduction of tocilizumab into central or peripheral veins via open or percutaneous routes.),(Exclusion Criteria: Excludes administration of other interleukin-6 antagonists (e.g., sarilumab) and routes of administration that do not involve open or percutaneous procedures (i.e. oral administration).)",
  "name": "COVID19ICD10PCSValueSetForAdministrationOfTocilizumab",
  "type": null,
  "experimental": "false",
  "resourceType": "ValueSet",
  "expansion": {
    "total": 2,
    "offset": 0,
    "contains": [ {
      "code": "XW033H5",
      "system": "http://www.cms.gov/Medicare/Coding/ICD10",
      "display": "Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5",
      "version": "2023"
    }, {
      "code": "XW043H5",
      "system": "http://www.cms.gov/Medicare/Coding/ICD10",
      "display": "Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5",
      "version": "2023"
    } ],
    "parameter": [ {
      "name": "count",
      "valueInteger": 1000
    }, {
      "name": "offset",
      "valueInteger": 0
    } ],
    "timestamp": "2023-06-29T16:41:42-04:00",
    "identifier": "urn:uuid:ec16e14a-8d8a-470f-aa3e-0cc01e1678b5"
  },
  "title": "COVID19 ICD10PCS Value Set for Administration of Tocilizumab",
  "package_version": "0.11.0",
  "extension": [ {
    "url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
    "valueString": "Clinical Architecture"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
    "valueDate": "2023-06-21"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
    "valueDate": "2020-12-17"
  } ],
  "status": "active",
  "id": "21bca142-088f-4dc2-ba91-f0aa2e822ad3",
  "kind": null,
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4019",
  "identifier": [ {
    "value": "urn:oid:2.16.840.1.113883.3.3616.200.110.102.4019",
    "system": "urn:ietf:rfc:3986"
  } ],
  "version": "20201217"
}